PDRX (PD-RX Pharmaceuticals) EBITDA Margin %: 0.00% (As of . 20)


What is PD-RX Pharmaceuticals EBITDA Margin %?

PD-RX Pharmaceuticals PDRX EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PD-RX Pharmaceuticals's EBITDA for the three months ended in . 20 was $0.00 Mil. PD-RX Pharmaceuticals's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, PD-RX Pharmaceuticals's EBITDA margin for the quarter that ended in . 20 was 0.00%.

PD-RX Pharmaceuticals  (OTCPK:PDRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

PD-RX Pharmaceuticals EBITDA Margin % Related Terms

PD-RX Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for PD-RX Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PD-RX Pharmaceuticals EBITDA Margin % Chart

PD-RX Pharmaceuticals Annual Data
Trend
EBITDA Margin %

PD-RX Pharmaceuticals Quarterly Data
EBITDA Margin %

PDRX vs SNYR, FZMD: EBITDA Margin % Comparison

For the Medical Distribution subindustry, PD-RX Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PD-RX Pharmaceuticals EBITDA Margin % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PD-RX Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PD-RX Pharmaceuticals's EBITDA Margin % falls into.


PD-RX Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PD-RX Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

PD-RX Pharmaceuticals's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
PD-RX Pharmaceuticals (PDRX) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PD-RX Pharmaceuticals and its competitors.
Is PD-RX Pharmaceuticals' EBITDA Margin % too high?
PD-RX Pharmaceuticals' current EBITDA Margin % is 0.00%.
How does PD-RX Pharmaceuticals' EBITDA Margin % compare to SNYR and FZMD?
PD-RX Pharmaceuticals' EBITDA Margin % of 0.00% can be compared against companies in the Medical Distribution industry. The industry median EBITDA Margin % is 4.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PD-RX Pharmaceuticals and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PD-RX Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PD-RX Pharmaceuticals stock overvalued right now?
PD-RX Pharmaceuticals (PDRX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PD-RX Pharmaceuticals (PDRX), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PD-RX Pharmaceuticals Business Description

Address 727 North Ann Arbor Avenue, Oklahoma City, OK, USA, 73127-5822
PD-RX Pharmaceuticals Inc provides and distributes a complete line of brand and generic pharmaceuticals, unit dose products, unit of use, injectables, creams, ointments, and medical and surgical supplies.